| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Departments of Pathology [C. T. L., Z. B. K.], Oral Pathology, Radiology, and Medicine [Z. B. K.], and the Immunology and Molecular Biology Graduate Programs [C. T. L.], University of Iowa, Iowa City, Iowa 52242
Human leukocyte antigen (HLA) class I molecules on hematopoietic cancers and melanomas inhibit attack by natural killer lymphocytes, but previous studies have not consistently demonstrated that carcinoma cells are protected by HLA class I expression. We investigated whether HLA class I molecules protect oral and pharyngeal squamous cell carcinoma cells from natural killer lymphocyte attack. Squamous cell carcinoma cell lines expressed varying levels of HLA class I, which correlated inversely with cytolysis by natural killer-enriched polyclonal lymphocytes. Cytolysis was increased by the presence of anti-HLA class I blocking monoclonal antibody (mAb). Subclones of the NK-92 human natural killer lymphoma cell line were derived by treatment with 5-aza-2'-deoxycytidine and limiting dilution cloning. NK-92 subclones expressed distinct sets of HLA class I-specific receptors. Some NK-92 subclones differentially lysed hematopoietic cells and squamous cell carcinoma cells, even in the presence of anti-HLA class I blocking mAb. This suggests that natural killer cells recognize different non-HLA ligands on hematopoietic and squamous cell carcinoma cells. In the presence of anti-HLA class I monoclonal antibody, other NK-92 subclones increased cytolysis of squamous cell carcinoma cells with moderate-to-high HLA class I levels. Anti-HLA class I mAb also increased natural killer cell attack of squamous cell carcinoma cells that were adherent to plastic. These data suggest that natural killer cell recognition of squamous cell carcinoma cells depends upon the balance of stimulatory and inhibitory ligands.
This article has been cited by other articles:
|
|
 |
|
  L. Binyamin, R. K. Alpaugh, T. L. Hughes, C. T. Lutz, K. S. Campbell, and L. M. Weiner Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy J. Immunol., May 1, 2008; 180(9): 6392 - 6401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, B. Grzywacz, D. Sukovich, V. McCullar, Q. Cao, A. B. Lee, B. R. Blazar, D. N. Cornfield, J. S. Miller, and M. R. Verneris The unexpected effect of cyclosporin A on CD56+CD16 and CD56+CD16+ natural killer cell subpopulations Blood, September 1, 2007; 110(5): 1530 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jewett, C. Head, and N.A. Cacalano Emerging Mechanisms of Immunosuppression in Oral Cancers Journal of Dental Research, December 1, 2006; 85(12): 1061 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-W. Chan, J. S. Miller, M. B. Moore, and C. T. Lutz Epigenetic Control of Highly Homologous Killer Ig-Like Receptor Gene Alleles J. Immunol., November 1, 2005; 175(9): 5966 - 5974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Stewart, J. van Bergen, and J. Trowsdale Different and Divergent Regulation of the KIR2DL4 and KIR3DL1 Promoters J. Immunol., June 15, 2003; 170(12): 6073 - 6081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G. Chiorean, S. J. Dylla, K. Olsen, T. Lenvik, Y. Soignier, and J. S. Miller BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs) Blood, May 1, 2003; 101(9): 3527 - 3533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-W. Chan, Z. B. Kurago, C. A. Stewart, M. J. Wilson, M. P. Martin, B. E. Mace, M. Carrington, J. Trowsdale, and C. T. Lutz DNA Methylation Maintains Allele-specific KIR Gene Expression in Human Natural Killer Cells J. Exp. Med., January 20, 2003; 197(2): 245 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Imboden, K. R. Murphy, A. L. Rakhmilevich, Z. C. Neal, R. Xiang, R. A. Reisfeld, S. D. Gillies, and P. M. Sondel The Level of MHC Class I Expression on Murine Adenocarcinoma Can Change the Antitumor Effector Mechanism of Immunocytokine Therapy Cancer Res., February 1, 2001; 61(4): 1500 - 1507. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
